Insmed (NASDAQ:INSM) Coverage Initiated at Barclays

Barclays started coverage on shares of Insmed (NASDAQ:INSM) in a report issued on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $231.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective indicates a potential upside of 48.18% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Wolfe Research set a $167.00 price objective on shares of Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Cantor Fitzgerald upped their target price on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Redburn Partners set a $263.00 price target on Insmed in a research report on Thursday, December 4th. Rothschild Redb upgraded Insmed to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, Guggenheim lowered their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Insmed presently has a consensus rating of “Buy” and a consensus target price of $205.83.

Insmed Stock Performance

Shares of Insmed stock opened at $155.89 on Tuesday. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The firm’s 50 day moving average is $181.91 and its two-hundred day moving average is $157.83. The firm has a market capitalization of $33.25 billion, a P/E ratio of -25.18 and a beta of 1.08.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company’s quarterly revenue was up 52.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.27) EPS. Research analysts forecast that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at approximately $10,089,889.56. This trade represents a 33.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares of the company’s stock, valued at $12,482,599.23. This represents a 13.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 296,799 shares of company stock worth $54,296,286. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Insmed

A number of institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its position in Insmed by 14.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 42,388 shares of the biopharmaceutical company’s stock worth $7,377,000 after acquiring an additional 5,337 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of Insmed by 15.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $201,000 after purchasing an additional 153 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Insmed by 3.1% during the 4th quarter. Arizona State Retirement System now owns 57,931 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 1,767 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Insmed by 467.1% in the 4th quarter. Geneos Wealth Management Inc. now owns 414 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 341 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of Insmed in the fourth quarter valued at about $229,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.